Merck keeps full control of the Keytruda market

Merck & Co. held 100% of global Keytruda market sales in 2024, according to The Business Research Company’s new market report. The report points to subcutaneous delivery, expanded indications and combination therapies as the main competitive levers shaping the immuno-oncology market through 2035.

Why it matters: - Keytruda remains a one-company market, giving Merck unusual pricing, launch and expansion power in one of oncology’s most important drug categories. - The report frames the competitive fight around faster administration, broader cancer coverage and patient-friendly delivery, all of which can affect adoption in clinics and cancer centers. - The market’s concentration also signals high barriers for rivals because biologics development, clinical trials and regulatory approval requirements remain steep.

What happened: - The Business Research Company released its Keytruda Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on July 12, 2026. - Merck & Co. Inc. led global Keytruda sales in 2024 with a 100% market share. - The report identifies Merck as the only company operating in the Keytruda market. - Merck’s immuno-oncology division is tied to PD-1 checkpoint inhibitor therapies used across multiple tumor types. - In November 2025, Merck received European Commission approval for a subcutaneous Keytruda formulation. - The new formulation is designed to speed administration compared with traditional intravenous delivery.

The details: - The report says the market is highly concentrated, with the top player accounting for all 2024 revenue. - Competitive positioning depends on clinical efficacy, safety, regulatory approvals, expanded indications and real-world evidence. - Rapid administration oncology injections are emerging as a major trend because they reduce clinic time and improve patient convenience. - The report says subcutaneous immunotherapy formulations, expanded indications, patient-centric options and checkpoint inhibitor innovation are the main strategies shaping the market. - Major raw material suppliers listed in the report include Lonza Group AG, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Cytiva, WuXi Biologics Co. Ltd., Samsung Biologics Co. Ltd., Boehringer Ingelheim BioXcellence, Catalent Inc., AGC Biologics, FUJIFILM Diosynth Biotechnologies and Recipharm AB. - Major wholesalers and distributors listed in the report include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health Inc., Phoenix Group, Walgreens Boots Alliance Inc., Celesio AG, Sinopharm Group Co. Ltd., Shanghai Pharmaceuticals Holding Co. Ltd., Zuellig Pharma Holdings Ltd., EVERSANA Company, FFF Enterprises Inc. and H. D. Smith. - Major end users listed in the report include Mayo Clinic, Cleveland Clinic, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital, Massachusetts General Hospital, Apollo Hospitals Enterprise Ltd., Fortis Healthcare Limited, Tata Memorial Hospital, Kaiser Permanente and Asan Medical Center. - The report also highlights new 2026 features including market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, hotspot infographics and updated graphics and tables. - The Business Research Company says it has published more than 30,000 reports across 27 industries and 60+ geographies. - The company says its research is powered by 1.5 million datasets, secondary research and interviews with industry leaders.

Between the lines: - A 100% share suggests Keytruda is less a competitive market and more a product ecosystem centered on Merck’s regulatory and commercial footprint. - The shift toward subcutaneous dosing shows how much convenience and administration speed now matter in oncology, not just efficacy. - The supplier and distributor lists show how broad the commercial and manufacturing network around a single therapy can be, even when one company owns the brand. - The report’s focus on expanded indications suggests future growth will come more from label expansion and formulation changes than from direct brand competition.

What's next: - Merck is expected to keep leaning on formulation upgrades, broader indications and combination strategies to defend and extend Keytruda’s position. - The report suggests more clinical development and collaboration activity as immuno-oncology demand rises. - Market watchers will be looking for additional regulatory decisions on faster-delivery Keytruda formats and new tumor-type approvals. - The Business Research Company is promoting a full report and sample request for more detailed market analysis: the full report and request a sample.

The bottom line: - Keytruda’s market is still entirely Merck’s, and the next phase of competition is likely to be about how fast, how easily and how broadly the drug can be delivered to patients.